[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prp":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,73,103,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100640127","augmentation-of-arthroscopic-rotator-cuff-repair-with-reimplantation-of-subacromial-bursa-tissue-and-platelet-rich-plasma-100640127",false,"NCT07589478","Augmentation of Arthroscopic Rotator Cuff Repair With Reimplantation of Subacromial Bursa Tissue and Platelet-Rich Plasma","ΕΝΙΣΧΥΣΗ ΑΡΘΡΟΣΚΟΠΙΚΗΣ ΣΥΡΡΑΦΗΣ ΣΤΡΟΦΙΚΟΥ ΠΕΤΑΛΟΥ ΜΕ ΕΠΑΝΕΜΦΥΤΕΥΣΗ ΙΣΤΟΥ ΤΟΥ ΥΠΑΚΡΩΜΙΑΚΟΥ ΘΥΛΑΚΟΥ ΚΑΙ ΠΛΑΣΜΑΤΟΣ ΠΛΟΥΣΙΟΥ ΣΕ ΑΙΜΟΠΕΤΑΛΙΑ","Inclusion Criteria Adult patients aged ≥18 years. Patients undergoing arthroscopic rotator cuff repair. Patients with a full-thickness, isolated, primary tear of the supraspinatus tendon.\n\nPatients considered eligible for arthroscopic rotator cuff repair using suture anchors.\n\nAbility and willingness to provide written informed consent. Willingness and ability to comply with the study protocol and scheduled follow-up visits.\n\nExclusion Criteria Partial-thickness rotator cuff tears. Massive or irreparable rotator cuff tears. Revision rotator cuff repair. Concomitant tears of the subscapularis tendon, infraspinatus tendon, long head of the biceps tendon requiring surgical treatment, or glenoid labrum.\n\nPrevious surgery on the affected shoulder. Glenohumeral osteoarthritis or advanced cuff tear arthropathy. Active infection or systemic inflammatory disease affecting the shoulder. Use of other biological augmentation techniques during surgery, such as collagen patch, stem cells, bone marrow aspirate concentrate, or other scaffold-based augmentation.\n\nInability to provide informed consent. Inability or unwillingness to comply with the postoperative rehabilitation protocol or follow-up schedule.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this observational study is to evaluate the clinical and radiographic outcomes of the biological enhancement of the arthroscopic rotator cuff repair with stem cells from the acromial bursa and PRP in individuals who undergo arthroscopic cuff repair The main question it aims to answer is:\n\nDo the stems cells from the acromial bursa and PRP promote healing and produce better results in arthroscopic cuff repair? Researchers will compare this population to three others the first do bnot receive any biological enchancement, the second receive only stem cells and the third receive only PRP to see if there are any differences.",[26,27,28,29],"Cuff Injury, Rotator","Arthroscopic Surgical Procedures","Stem Cell","PRP","NOT_YET_RECRUITING","2026-05-17",{"date":33,"type":34},"2026-05-19","ACTUAL",{"date":36,"type":20},"2026-05",{"date":38,"type":20},"2028-02",{"name":40,"class":41},"National and Kapodistrian University of Athens","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100629108","phase-2-comparison-of-functional-outcomes-following-arthroscopic-acl-reconstruction-with-peroneus-longus-autograft-with-and-without-intra-articular-platelet-rich-plasma-injection-100629108","NCT07470359","Comparison of Functional Outcomes Following Arthroscopic ACL Reconstruction With Peroneus Longus Autograft With and Without Intra-articular Platelet-Rich Plasma Injection.","Comparison of Functional Outcomes Following Arthroscopic ACL Reconstruction With Peroneus Longus Autograft With and Without Intra-articular Platelet-Rich Plasma Injection: A Randomized Controlled Trial","Inclusion Criteria: Age between 18 and 50 years. Diagnosis of a primary, complete ACL tear requiring reconstruction. Willingness to undergo arthroscopic ACL reconstruction with peroneus longus autograft.\n\nActive individuals participating in sports or regular physical activity. Willingness to provide informed consent and adhere to the study protocol, including follow-up visits and rehabilitation.\n\nAbility to understand and complete study questionnaires. - Exclusion Criteria: Previous knee surgery on the affected limb. Concomitant ligamentous injuries requiring additional reconstruction (e.g., PCL, MCL, LCL Grade III).\n\nSignificant chondral damage (Outerbridge grade \\> 2 on pre-operative MRI or intra-operative assessment).\n\nPre-existing knee osteoarthritis (Kellgren-Lawrence grade \\> 2). Systemic inflammatory conditions (e.g., rheumatoid arthritis). Bleeding disorders or coagulopathies. Current use of anticoagulants. Corticosteroid injection into the knee within 6 weeks prior to surgery. Pregnancy or lactation. Inability to comply with the rehabilitation protocol. Infection or history of infection in the affected knee. History of previous contralateral ACL injury (to isolate primary injury outcomes).\n\n\\-","50 Years",{"count":51,"type":20},60,[53],"PHASE2","This prospective RCT investigates if a single 4 ml intra-articular PRP injection improves knee function after ACL reconstruction using peroneus longus autograft. In Pakistan's resource-limited context, 88 patients (18-50 years) with isolated ACL tears receive either PRP or saline during surgery, then randomized equally. KOOS4 scores compared at 3, 6, and 12 months via ANCOVA (adjusted baseline, α=0.05). Positive results could establish affordable enhancement for recovery and guide practice in similar settings.",[56,57,29],"ACL Reconstruction","Intraarticular Injection",[59,60],"Anterior Cruciate Ligament, ACL Reconstruction, Peroneus Longus Autograft, Platelet-Rich Plasma, Intra-articular Injection","Randomized Controlled Trial, KOOS4 Score, Functional Outcomes, Graft Healing, Resource-Limited Settings","RECRUITING","2026-03-10",{"date":64,"type":34},"2026-03-13",{"date":66,"type":34},"2026-02-20",{"date":68,"type":20},"2027-11-30",{"name":70,"class":71},"Lahore General Hospital","OTHER_GOV",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":49,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":72},"100470939","phase-3-prp-in-aclr-to-prevent-ptoa-100470939","NCT05412381","PRP in ACLR to Prevent PTOA","Platelet Rich Plasma (PRP) Treatment of the Anterior Cruciate Ligament Injured Knee to Decrease the Risk of Post-traumatic Osteoarthritis (PTOA): a Randomized Double-blind Controlled Trial","Inclusion Criteria:\n\n* Acute ACL injury within 6 weeks of presentation\n* Age 14-50\n* Male or female\n* Meniscus injury that can be treated with meniscectomy or repair (the lack of meniscus injury will not exclude patients)\n\nExclusion Criteria:\n\n* Prior ACL reconstruction\n* Prior cartilage repair procedure\n* Prior meniscus surgery within 12 months\n* Prior steroid, hyaluronic acid, or PRP injection within 6 months\n* Other ligament injury requiring repair\n* Any cartilage lesion requiring repair\n* Any cartilage lesion greater than grade 2 (partial thickness injury)\n* History of inflammatory arthritis or joint sepsis\n* Non English speakers","14 Years",{"count":82,"type":20},56,[84],"PHASE3","The purpose of our study is to examine the effect of platelet-rich-plasma (PRP) injection on the short-term resolution of post-injury inflammation (biomarkers) and improvement in joint function in patients with acute ACL injury. This RCT has been powered based on the questionnaire KOOS Jr. but it is considered a 'pilot study' in terms of the lab analysis proposed.",[87,88,29],"Anterior Cruciate Ligament Injuries","Post-traumatic Osteoarthritis",[90,91,92,93],"platelet-rich plasma","regenerative medicine","anterior cruciate ligament reconstruction","post-traumatic osteoarthritis","2026-02-11",{"date":96,"type":34},"2026-02-13",{"date":98,"type":34},"2022-06-27",{"date":100,"type":20},"2026-12-31",{"name":102,"class":41},"Hospital for Special Surgery, New York",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100599421","prp-yield-and-platelet-distribution-with-edta-100599421","NCT07084272","PRP Yield and Platelet Distribution With EDTA","A Comparison Study of ACD-A and EDTA Anticoagulation of Platelet-rich Plasma: Yields and Platelet Distribution","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n* blood dyscrasias",true,"75 Years",{"count":51,"type":20},"OBSERVATIONAL","We will test and compare the platelet distribution after centrifugation and the platelet yield of ACD-A and EDTA anticoagulated blood",[29],[29,117,118,119],"ACD-A","EDTA","platelets","2025-07-16",{"date":122,"type":34},"2025-07-24",{"date":124,"type":20},"2025-08",{"date":126,"type":20},"2025-12-31",{"name":128,"class":129},"Harrison, Theodore, M.D.","INDIV",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":137,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":72},"100552379","the-efficacy-and-safety-of-pulsed-radiofrequency-combined-with-platelet-rich-plasma-for-the-trigeminal-neuralgia-100552379","NCT06472323","The Efficacy and Safety of Pulsed Radiofrequency Combined With Platelet-rich Plasma for the Trigeminal Neuralgia","The Efficacy and Safety of Pulsed Radiofrequency(PRF) Combined With Platelet-rich Plasma Versus PRF Alone for the Trigeminal Neuralgia","Inclusion Criteria:\n\n1. The diagnosis of TN was established according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria (1).\n2. Aged 18 to 75 years.\n3. Had a score of at least 4 on a Numeric Rating Scale (NRS-11) (NRS; range, 0-10; higher scores indicate more severe pain) and could't be alleviated effectively by means of conservative medical therapy, such as carbamazepine, oxcarbazepine.\n4. Agreed to sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients presenting classic TN or secondary TN (i.e., multiple sclerosis).\n2. Infection at the site of needle entry or systemic infecting.\n3. A history of psychiatric disease.\n4. Disorder indicated in the results of routine blood tests, hepatic function, renal function, coagulation function, electrocardiogram, or chest x-ray.\n5. Serious systemic diseases such as uncontrolled hypertension or diabetes, and cardiac dysfunction (New York Heart Association grade II-III).\n6. A history of abuse of narcotics.\n7. A history of receiving CRF to the Gasserian ganglion or peripheral branches, glycerol rhizolysis, balloon compression, Gamma knife, or any other neuroablative treatments.\n8. A history of receiving microvascular decompression.\n9. Use of anticoagulants or antiplatelet agent, eg. acetylsalicylic acid.",{"count":138,"type":20},270,"Trigeminal neuralgia (TN), characterized by brief, recurrent paroxysms of lancinating pain in the distribution of 1 or more branches of the trigeminal nerve (fifth cranial nerve \\[CNV\\]), is one of the most common, severe forms of neuropathic pain. Current standard of care for TN is the sodium channel blockers such as carbamazepine or oxcarbazepine. Surgical treatments involve percutaneous procedures, stereotactic radiosurgery and open surgical treatment. Each of these treatments have drawback. In recent years, pulsed radiofrequency (PRF) has been shown to be a promising treatment option for TN. But it was reported that the long-term outcomes of PRF was not satisfactory. Thus, there is an overwhelming need for finding a safe, nondestructive treatment option that is more effective for TN. PRP releases a variety of bioactive factors and adhesion proteins, which are responsible for activating hemostatic cascade reaction, synthesizing new connective tissue and vascular reconstruction, to initiate tissue repair processes. Autologous platelet-rich plasma (PRP) is the processed liquid fraction of autologous peripheral blood with a platelet concentration above the baseline. Studies have shown that it can reduce inflammation and promote nerve repair so it has also shown broad prospects in treating neuropathic pain. In 2012, Doss AX. published a case report indicated that PRP might be effective in TN treatment. In 2023, a randomized controlled study showed that CT-guided PRF combined with PRP can effectively treat postherpetic neuralgia (PHN), and the therapeutic effect is better than that of traditional PRF combined with glucocorticoid therapy in patients with PHN, which is similar to TN in pathology. Thus, we suppose that PRF combined with PRP might show better effectiveness than PRF alone for TN and conducted a prospective trail comparing the clinical efficacy and safety of PRP combined with PRF versus PRF alone. This study is designed as a prospective cohort study, open-label study with a 12 months follow-up period, to compare the efficacy of PRF combined with PRP versus PRP alone for TN treatment.",[141,29],"Trigeminal Neuralgia, Idiopathic","2025-03-31",{"date":144,"type":34},"2025-04-01",{"date":146,"type":34},"2024-08-01",{"date":148,"type":20},"2026-09-30",{"name":150,"class":41},"Beijing Tiantan Hospital"]